Pneumothorax as a late complication of COVID-19
DOI:
https://doi.org/10.1590/S1678-9946202062061Keywords:
COVID-19, SARS-CoV-2, Pneumonia, PneumothoraxAbstract
In late 2019, a novel coronavirus initially related to a cluster of severe pneumonia cases in China was identified. COVID-19 cases have rapidly spread to multiple countries worldwide. We present a typical laboratory confirmed case of COVID-19 pneumonia, that was hospitalized due to hypoxemia but did not require mechanical ventilation. Although initially the patient was evaluated with a favorable outcome, in the third week of the disease, the symptomatology deteriorated due to a massive hypertensive pneumothorax with no known previous risk factor. Since the first cases of COVID-19 have been described, pneumothorax was characterized as a potential, though uncommon, complication. It has been reported that diffuse alveolar injury caused by SARS‑CoV-2 can cause alveolar rupture, produce air leakage and interstitial emphysema. Although uncommon, pneumothorax should be listed as a differential diagnosis for COVID-19 patients with sudden respiratory decompensation. As a life-threatening event, it requires prompt recognition and expeditious treatment.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Revista do Instituto de Medicina Tropical de São Paulo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.